Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.36 |
| ▸ | RAB9A | P51151 | 5/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | RGS12 | O14924 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7112244 | 0.88 | EHMT2 (0.35) | NPC1RAB9APKMEHMT2EHMT1 | |
| SCHEMBL561821 | 0.88 | RAB9A (0.37) | NPC1RAB9AEHMT2EHMT1APOBEC3G | |
| SCHEMBL465750 | 0.83 | LMNA (0.37) | NPC1RAB9APKMEHMT2EHMT1 | |
| SCHEMBL1888896 | 0.82 | ALDH1A1 (0.37) | NPC1RAB9APKMALDH1A1HPGD | |
| SCHEMBL11122105 | 0.81 | EHMT2 (0.39) | NPC1RAB9AEHMT2EHMT1APOBEC3G | |
| SCHEMBL4184231 | 0.80 | MEN1 (0.37) | NPC1RAB9AEHMT2EHMT1APOBEC3G | |
| SCHEMBL73690 | 0.80 | EHMT2 (0.37) | NPC1RAB9AEHMT2EHMT1APOBEC3G | |
| SCHEMBL1679370 | 0.78 | EHMT2 (0.35) | RAB9AEHMT2EHMT1APOBEC3GALDH1A1 | |
| SCHEMBL8328957 | 0.78 | ALDH1A1 (0.39) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL29386113 | 0.77 | MAPT (0.36) | NPC1RAB9APKMEHMT2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097529-A1 | METHODS OF SELECTING AND PRODUCING MODIFIED TOXINS, CONJUGATES CONTAINING MODIFIED TOXINS AND USES THEREOF | Osprey Pharmaceuticals USA, Inc. (US) | 2009-09-09 | — | — | EP | claimed |
| WO-2008080218-A9 | METHODS OF SELECTING AND PRODUCING MODIFIED TOXINS, CONJUGATES CONTAINING MODIFIED TOXINS AND USES THEREOF | OSPREY PHARMACEUTICALS LTD (CA) | 2008-08-28 | — | — | WO | claimed |
| WO-2008080218-A1 | METHODS OF SELECTING AND PRODUCING MODIFIED TOXINS, CONJUGATES CONTAINING MODIFIED TOXINS AND USES THEREOF | OSPREY PHARMACEUTICALS USA, INC. (US) | 2008-07-10 | — | — | WO | claimed |
| EP-1819359-B1 | ANTI-INTEGRIN IMMUNOCONJUGATES, METHODS OF THEIR PRODUCTION AND THEIR USE | JANSSEN BIOTECH INC (US) | 2015-03-18 | — | — | EP | disclosed |
| US-8603483-B2 | Anti-integrin immunoconjugates, methods and uses | JANSSEN BIOTECH, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| EP-1819359-A2 | ANTI-INTEGRIN IMMUNOCONJUGATES, METHODS AND USES | Centocor, Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006062779-A2 | ANTI-INTEGRIN IMMUNOCONJUGATES, METHODS AND USES | CENTOCOR, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| US-20060127407-A1 | Anti-integrin immunoconjugates, methods and uses | JANSSEN BIOTECH, INC. | 2006-06-15 | — | — | US | disclosed |
| WO-2003044179-A2 | NUCLEIC ACID MOLECULES ENCODING SERINE PROTEASE 17, THE ENCODED POLYPEPTIDES AND METHODS BASED THEREON | DENDREON SAN DIEGO LLC (US) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060127407-A1 | Anti-integrin immunoconjugates, methods and uses | ITGB3, ITGB5, ITGB4 | NPC1 3736/4885RAB9A 1354/4885PKM 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.